Neuroimaging in Psychiatric Disorders

Neurotherapeutics

Volumn 8, Issue 1, 2011, Pages 93-102

  Masdeu, Joseph C ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Depression; Drug development; Magnetic resonance imaging; Positron emission tomography; Schizophrenia; Single photon emission tomography

Indexed keywords

4 AMINOBUTYRIC ACID; 6 FLUORODOPA F 18; ARIPIPRAZOLE; BENZODIAZEPINE; CARBON 11; CLOMIPRAMINE; FLUORODEOXYGLUCOSE F 18; IODINE 123; IOFLUPANE I 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; PITTSBURGH COMPOUND B; RACLOPRIDE C 11; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; COGNITIVE DEFECT; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DRUG DEVELOPMENT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; MAJOR DEPRESSION; MENTAL DISEASE; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; DIAGNOSTIC IMAGING; DRUG DISCOVERY; HUMANS; MENTAL DISORDERS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79955556925     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13311-010-0006-0     Document Type: Article

References (57)

1. Agarwal N, Port JD, Bazzocchi M, Renshaw PF. Update on the use of MR for assessment and diagnosis of psychiatric diseases. Radiology 2010; 255: 23-41.
2. Inkster B, Nichols TE, Saemann PG, et al. Pathway-based approaches to imaging genetics association studies: Wnt signaling, GSK3beta substrates and major depression. Neuroimage 2010; 53: 908-917.
3. Bunevicius A, Deltuva VP, Deltuviene D, Tamasauskas A, Bunevicius R. Brain lesions manifesting as psychiatric disorders: eight cases. CNS Spectr 2008; 13: 950-958.
4. Sherwin I, Peron-Magnan P, Bancaud J, Bonis A, Talairach J. Prevalence of psychosis in epilepsy as a function of the laterality of the epileptogenic lesion. Arch Neurol 1982; 39: 621-625.
5. Boone KB, Miller BL, Rosenberg L, Durazo A, McIntyre H, Weil M. Neuropsychological and behavioral abnormalities in an adolescent with frontal lobe seizures. Neurology 1988; 38: 583-586.
6. Moise D, Madhusoodanan S. Psychiatric symptoms associated with brain tumors: a clinical enigma. CNS Spectr 2006; 11: 28-31.
7. Albert DJ, Walsh ML, Jonik RH. Aggression in humans: what is its biological foundation? Neurosci Biobehav Rev 1993; 17: 405-425.
8. Grafman J, Vance SC, Weingartner H, Salazar AM, Amin D. The effects of lateralized frontal lesions on mood regulation. Brain 1986; 109: 1127-1148.
9. Masdeu JC, Zubieta JL, Arbizu J. Neuroimaging as a marker of the onset and progression of Alzheimer's disease. J Neurol Sci 2005; 236: 55-64.
10. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725.
11. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007; 130: 2616-2635.
12. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007; 69: 871-877.
13. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001; 286: 2120-2127.
14. Jagust W, Thisted R, Devous MD, Sr., et al. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology 2001; 56: 950-956.
15. Lowe VJ, Kemp BJ, Jack CR, Jr., et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 2009; 50: 878-886.
16. Reisch T, Brekenfeld C, Barth A. A case of hydrocephalus occlusus presenting as bipolar disorder. Acta Psychiatr Scand 2005; 112: 159-162; discussion 162-153.
17. McMurtray AM, Chen AK, Shapira JS, et al. Variations in regional SPECT hypoperfusion and clinical features in frontotemporal dementia. Neurology 2006; 66: 517-522.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). Arlington, Va: American Psychiatric Association; 2000.
19. Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 2009; 34: 74-89.
20. Sun D, van Erp TG, Thompson PM, et al. Elucidating a magnetic resonance imaging-based neuroanatomic biomarker for psychosis: classification analysis using probabilistic brain atlas and machine learning algorithms. Biol Psychiatry 2009; 66: 1055-1060.
21. Meisenzahl EM, Koutsouleris N, Bottlender R, et al. Structural brain alterations at different stages of schizophrenia: a voxel-based morphometric study. Schizophr Res 2008; 104: 44-60.
22. Thompson PM, Bartzokis G, Hayashi KM, et al. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cereb Cortex 2009; 19: 1107-1123.
23. Eisenberg DP, Sarpal D, Kohn PD, et al. Catechol-o-methyltransferase valine(158)methionine genotype and resting regional cerebral blood flow in medication-free patients with schizophrenia. Biol Psychiatry 2010; 67: 287-290.
24. Blasi G, Taurisano P, Papazacharias A, et al. Nonlinear response of the anterior cingulate and prefrontal cortex in schizophrenia as a function of variable attentional control. Cereb Cortex 2010; 20: 837-845.
25. Meyer-Lindenberg AS, Olsen RK, Kohn PD, et al. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch Gen Psychiatry 2005; 62: 379-386.
26. Benetti S, Mechelli A, Picchioni M, Broome M, Williams S, McGuire P. Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state. Brain 2009; 132: 2426-2436.
27. Whitfield-Gabrieli S, Thermenos HW, Milanovic S, et al. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci USA 2009; 106: 1279-1284.
28. Savitz JB, Drevets WC. Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience 2009; 164: 300-330.
29. Gron G, Bittner D, Schmitz B, Wunderlich AP, Riepe MW. Subjective memory complaints: objective neural markers in patients with Alzheimer's disease and major depressive disorder. Ann Neurol 2002; 51: 491-498.
30. Wong DF, Tauscher J, Grunder G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009; 34: 187-203.
31. Passchier J, Gentile G, Porter R, et al. Identification and evaluation of [11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography. Synapse 2010; 64: 542-549.
32. 11C]GSK931145: A new PET ligand for glycine transporter 1. Neuro-Receptor Meeting. Pittsburgh 2008.
33. Lesko LJ, Atkinson AJ, Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001; 41: 347-366.
34. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514-520.
35. Grunder G, Landvogt C, Vernaleken I, et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 2006; 31: 1027-1035.
36. Kessler RM, Ansari MS, Riccardi P, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006; 31: 1991-2001.
37. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002; 5: 267-271.
38. Slifstein M, Kolachana B, Simpson EH, et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [(11)C]NNC112 and PET. Mol Psychiatry 2008; 13: 821-827.
39. Catafau AM, Suarez M, Bullich S, et al. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET. Neuroimage 2009; 46: 447-458.
40. Kessler RM, Woodward ND, Riccardi P, et al. Dopamine D(2) receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 2009; 65: 1024-1031.
41. Kegeles LS, Slifstein M, Frankle WG, et al. Dose-occupancy study of striatal and extrastriatal dopamine D(2) receptors by aripiprazole in schizophrenia with PET and [(18)F]Fallypride. Neuropsychopharmacology 2008; 33: 3111-3125.
42. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004; 19: 1175-1182.
43. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97: 8104-8109.
44. Abi-Dargham A, Giessen EV, Slifstein M, Kegeles LS, Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 2009; 65: 1091-1093.
45. Woodward ND, Zald DH, Ding Z, et al. Cerebral morphology and dopamine D2/D3 receptor distribution in humans: a combined [18F]fallypride and voxel-based morphometry study. Neuroimage 2009; 46: 31-38.
46. Buchsbaum MS, Christian BT, Lehrer DS, et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 2006; 85: 232-244.
47. Catafau AM, Perez V, Plaza P, et al. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. Psychopharmacology (Berl) 2006; 189: 145-153.
48. Pissarek MB, Oros-Peusquens AM, Schramm NU. Challenge by the murine brain: multi-pinhole SPECT of 123I-labelled pharmaceuticals. J Neurosci Methods 2008; 168: 282-292.
49. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002; 27: 248-259.
50. Suhara T, Takano A, Sudo Y, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 2003; 60: 386-391.
51. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-265.
52. Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006; 59: 216-223.
53. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 2006; 59: 816-820.
54. Yoon SJ, Lyoo IK, Haws C, Kim TS, Cohen BM, Renshaw PF. Decreased glutamate/glutamine levels may mediate cytidine's efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2009; 34: 1810-1818.
55. Kozel FA, Johnson KA, Nahas Z, et al. Fractional anisotropy changes after several weeks of daily left high-frequency repetitive transcranial magnetic stimulation of the prefrontal cortex to treat major depression. J ECT 2010 Oct 1. [Epub ahead of print].
56. Coenen VA, Honey CR, Hurwitz T, et al. Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson's disease. Neurosurgery 2009; 64: 1106-1114; discussion 1114-1105.
57. Masdeu J. Neuroimaging of disorders leading to dementia. Continuum (AAN) 2008; 14: 144-163.